Search form
Search
contact us
Navigation
home
boards
Jobs
job ratings
cp wire
medtech news
pharmagather
catering
advertise
whistleblower info
pharmaceutical fraud
medical device | DME fraud
clinical lab fraud
False Claims Act
Legal Help
login/register
You are here
Home
»
companies
» sitravantinib
sitravantinib
Mirati's long wait for next lung cancer med ends in phase 3 failure
Mirati's long wait for next lung cancer med ends in phase 3 failure
Fierce Biotech
Mirati Therapeutics
clinical trials
sitravantinib
lung cancer
non small cell lung cancer
Flag link:
Amid Buyout Buzz, Mirati Pushes Phase III NSCLC Study to Final Analysis
Amid Buyout Buzz, Mirati Pushes Phase III NSCLC Study to Final Analysis
BioSpace
Mirati Therapeutics
clinical trials
M&A
non-small cell lung cancer
sitravantinib
Flag link:
Mirati's Sitravatinib Shows Promising Phase II Results in Urothelial Cancer Patients
Mirati's Sitravatinib Shows Promising Phase II Results in Urothelial Cancer Patients
BioSpace
Mirati Therapeutics
sitravantinib
ESMO
urothelial cancer
Flag link:
Mirati's sitravatinib in combination with nivolumab shows 37% response rate in urothelial cancer
Mirati's sitravatinib in combination with nivolumab shows 37% response rate in urothelial cancer
Seeking Alpha
ESMO
Mirati Therapeutics
clinical trials
sitravantinib
Opdivo
urothelial cancer
Flag link:
